data integrity issues in bioequivalence studies
Published 3 years ago • 895 plays • Length 25:57Download video MP4
Download video MP3
Similar videos
-
18:22
blinding of bioequivalence trials (9of11) gcp data integrity
-
19:18
impact of data integrity issues on pharmacology/toxicology studies in andas
-
24:19
panel on emerging use of modeling and simulation for bioequivalence
-
17:43
bioavailability/bioequivalence site evaluation during the pandemic
-
0:54
a new possible way to evaluate bioequivalence of topical drugs
-
22:06
overview of data integrity (4of11) gcp data integrity workshop
-
19:51
the data management plan – pulling it all together (7of11) gcp data integrity workshop
-
23:31
case studies: inadequate bioequivalence studies (18of28) generic drugs forum – apr. 3-4, 2019
-
56:11
quality and control of clinical trial data (6of11) gcp data integrity workshop
-
23:22
data integrity from international perspectives (2of11) gcp data integrity workshop
-
16:23
bioanalysis of unstable analytes in pharmacokinetic be studies for andas - bioanalysis 2020
-
3:34
fda charges data integrity issues in wockhardt factories
-
20:45
in vitro bioequivalence studies of topical drug products: challenges and promises of ivrt and ivpt
-
5:20
data requirements for biosimilars
-
41:33
fda inspection trends
-
19:32
assessment of complex drug product – physicochemical characteristics to support in vitro be studies
-
45:10
unblinding – let me count the ways… (8of11) gcp data integrity
-
1:56:15
understanding fda inspections and data
-
33:03
bioanalytical inspections: overview and case studies – june 17, 2019